nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—UGT1A9—Irinotecan—pancreatic cancer	0.0916	0.123	CbGbCtD
Dapagliflozin—UGT2B7—Epirubicin—pancreatic cancer	0.0891	0.12	CbGbCtD
Dapagliflozin—CYP1A1—Dacarbazine—pancreatic cancer	0.0623	0.0839	CbGbCtD
Dapagliflozin—CYP2A6—Tamoxifen—pancreatic cancer	0.058	0.0781	CbGbCtD
Dapagliflozin—CYP1A1—Tamoxifen—pancreatic cancer	0.0495	0.0668	CbGbCtD
Dapagliflozin—CYP2A6—Fluorouracil—pancreatic cancer	0.0427	0.0576	CbGbCtD
Dapagliflozin—CYP1A1—Erlotinib—pancreatic cancer	0.0421	0.0568	CbGbCtD
Dapagliflozin—CYP1A2—Dacarbazine—pancreatic cancer	0.0278	0.0375	CbGbCtD
Dapagliflozin—CYP1A2—Tamoxifen—pancreatic cancer	0.0221	0.0298	CbGbCtD
Dapagliflozin—CYP2C9—Tamoxifen—pancreatic cancer	0.0199	0.0269	CbGbCtD
Dapagliflozin—ABCB1—Tamoxifen—pancreatic cancer	0.0193	0.0261	CbGbCtD
Dapagliflozin—CYP1A2—Erlotinib—pancreatic cancer	0.0188	0.0254	CbGbCtD
Dapagliflozin—CYP2D6—Tamoxifen—pancreatic cancer	0.0182	0.0246	CbGbCtD
Dapagliflozin—ABCB1—Gemcitabine—pancreatic cancer	0.0167	0.0225	CbGbCtD
Dapagliflozin—ABCB1—Erlotinib—pancreatic cancer	0.0165	0.0222	CbGbCtD
Dapagliflozin—CYP1A2—Fluorouracil—pancreatic cancer	0.0163	0.022	CbGbCtD
Dapagliflozin—CYP2D6—Erlotinib—pancreatic cancer	0.0155	0.0209	CbGbCtD
Dapagliflozin—ABCB1—Irinotecan—pancreatic cancer	0.0149	0.02	CbGbCtD
Dapagliflozin—CYP2C9—Fluorouracil—pancreatic cancer	0.0147	0.0198	CbGbCtD
Dapagliflozin—CYP3A4—Tamoxifen—pancreatic cancer	0.0116	0.0156	CbGbCtD
Dapagliflozin—ABCB1—Docetaxel—pancreatic cancer	0.0109	0.0147	CbGbCtD
Dapagliflozin—ABCB1—Sunitinib—pancreatic cancer	0.0108	0.0146	CbGbCtD
Dapagliflozin—CYP3A4—Erlotinib—pancreatic cancer	0.00986	0.0133	CbGbCtD
Dapagliflozin—CYP3A4—Irinotecan—pancreatic cancer	0.0089	0.012	CbGbCtD
Dapagliflozin—ABCB1—Doxorubicin—pancreatic cancer	0.00812	0.0109	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—pancreatic cancer	0.00765	0.0103	CbGbCtD
Dapagliflozin—CYP3A4—Docetaxel—pancreatic cancer	0.00652	0.00879	CbGbCtD
Dapagliflozin—CYP3A4—Sunitinib—pancreatic cancer	0.00649	0.00875	CbGbCtD
Dapagliflozin—CYP3A4—Doxorubicin—pancreatic cancer	0.00486	0.00655	CbGbCtD
Dapagliflozin—Neoplasm—Docetaxel—pancreatic cancer	0.000559	0.00358	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Fluorouracil—pancreatic cancer	0.000556	0.00356	CcSEcCtD
Dapagliflozin—Malnutrition—Erlotinib—pancreatic cancer	0.000548	0.00351	CcSEcCtD
Dapagliflozin—Angina pectoris—Irinotecan—pancreatic cancer	0.000547	0.0035	CcSEcCtD
Dapagliflozin—Influenza—Gemcitabine—pancreatic cancer	0.000547	0.0035	CcSEcCtD
Dapagliflozin—Lung disorder—Doxorubicin—pancreatic cancer	0.000545	0.00349	CcSEcCtD
Dapagliflozin—Fungal infection—Epirubicin—pancreatic cancer	0.00054	0.00346	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Sunitinib—pancreatic cancer	0.000539	0.00345	CcSEcCtD
Dapagliflozin—Back pain—Tamoxifen—pancreatic cancer	0.000536	0.00343	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Sunitinib—pancreatic cancer	0.000536	0.00343	CcSEcCtD
Dapagliflozin—Urethral disorder—Sunitinib—pancreatic cancer	0.000535	0.00342	CcSEcCtD
Dapagliflozin—Back pain—Erlotinib—pancreatic cancer	0.00053	0.00339	CcSEcCtD
Dapagliflozin—Angina pectoris—Fluorouracil—pancreatic cancer	0.000524	0.00335	CcSEcCtD
Dapagliflozin—Phlebitis—Docetaxel—pancreatic cancer	0.000521	0.00333	CcSEcCtD
Dapagliflozin—Angioedema—Tamoxifen—pancreatic cancer	0.000506	0.00324	CcSEcCtD
Dapagliflozin—Fungal infection—Doxorubicin—pancreatic cancer	0.0005	0.0032	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Irinotecan—pancreatic cancer	0.000493	0.00316	CcSEcCtD
Dapagliflozin—Renal failure—Irinotecan—pancreatic cancer	0.000492	0.00315	CcSEcCtD
Dapagliflozin—Myocardial infarction—Irinotecan—pancreatic cancer	0.000491	0.00314	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Epirubicin—pancreatic cancer	0.000488	0.00313	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Gemcitabine—pancreatic cancer	0.000481	0.00308	CcSEcCtD
Dapagliflozin—Infestation NOS—Fluorouracil—pancreatic cancer	0.000479	0.00307	CcSEcCtD
Dapagliflozin—Infestation—Fluorouracil—pancreatic cancer	0.000479	0.00307	CcSEcCtD
Dapagliflozin—Renal failure—Gemcitabine—pancreatic cancer	0.000479	0.00307	CcSEcCtD
Dapagliflozin—Hypertension—Tamoxifen—pancreatic cancer	0.000479	0.00306	CcSEcCtD
Dapagliflozin—Extravasation—Epirubicin—pancreatic cancer	0.000478	0.00306	CcSEcCtD
Dapagliflozin—Myocardial infarction—Gemcitabine—pancreatic cancer	0.000478	0.00306	CcSEcCtD
Dapagliflozin—Malnutrition—Sunitinib—pancreatic cancer	0.000475	0.00304	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Fluorouracil—pancreatic cancer	0.000472	0.00302	CcSEcCtD
Dapagliflozin—Myocardial infarction—Fluorouracil—pancreatic cancer	0.00047	0.00301	CcSEcCtD
Dapagliflozin—Discomfort—Tamoxifen—pancreatic cancer	0.000466	0.00298	CcSEcCtD
Dapagliflozin—Urinary tract infection—Fluorouracil—pancreatic cancer	0.000466	0.00298	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.000464	0.00297	CcSEcCtD
Dapagliflozin—Back pain—Sunitinib—pancreatic cancer	0.000459	0.00294	CcSEcCtD
Dapagliflozin—Oedema—Tamoxifen—pancreatic cancer	0.000452	0.00289	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Doxorubicin—pancreatic cancer	0.000452	0.00289	CcSEcCtD
Dapagliflozin—Hyponatraemia—Docetaxel—pancreatic cancer	0.000451	0.00288	CcSEcCtD
Dapagliflozin—Nocturia—Epirubicin—pancreatic cancer	0.00045	0.00288	CcSEcCtD
Dapagliflozin—Infection—Tamoxifen—pancreatic cancer	0.000449	0.00288	CcSEcCtD
Dapagliflozin—Pain in extremity—Docetaxel—pancreatic cancer	0.000449	0.00287	CcSEcCtD
Dapagliflozin—Oedema—Erlotinib—pancreatic cancer	0.000448	0.00286	CcSEcCtD
Dapagliflozin—Infection—Erlotinib—pancreatic cancer	0.000445	0.00285	CcSEcCtD
Dapagliflozin—Extravasation—Doxorubicin—pancreatic cancer	0.000442	0.00283	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Irinotecan—pancreatic cancer	0.000441	0.00283	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Tamoxifen—pancreatic cancer	0.000437	0.0028	CcSEcCtD
Dapagliflozin—Skin disorder—Erlotinib—pancreatic cancer	0.000435	0.00278	CcSEcCtD
Dapagliflozin—Angioedema—Sunitinib—pancreatic cancer	0.000434	0.00278	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Gemcitabine—pancreatic cancer	0.000432	0.00277	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Gemcitabine—pancreatic cancer	0.00043	0.00275	CcSEcCtD
Dapagliflozin—Urethral disorder—Gemcitabine—pancreatic cancer	0.000429	0.00275	CcSEcCtD
Dapagliflozin—Dehydration—Docetaxel—pancreatic cancer	0.000417	0.00267	CcSEcCtD
Dapagliflozin—Nocturia—Doxorubicin—pancreatic cancer	0.000416	0.00266	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Docetaxel—pancreatic cancer	0.00041	0.00262	CcSEcCtD
Dapagliflozin—Hypertension—Sunitinib—pancreatic cancer	0.00041	0.00262	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Docetaxel—pancreatic cancer	0.000401	0.00257	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.000401	0.00257	CcSEcCtD
Dapagliflozin—Blood urea increased—Epirubicin—pancreatic cancer	0.000394	0.00252	CcSEcCtD
Dapagliflozin—Vaginal infection—Epirubicin—pancreatic cancer	0.000394	0.00252	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.000391	0.0025	CcSEcCtD
Dapagliflozin—Oedema—Sunitinib—pancreatic cancer	0.000387	0.00248	CcSEcCtD
Dapagliflozin—Constipation—Tamoxifen—pancreatic cancer	0.000387	0.00248	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000386	0.00247	CcSEcCtD
Dapagliflozin—Infection—Sunitinib—pancreatic cancer	0.000385	0.00246	CcSEcCtD
Dapagliflozin—Constipation—Erlotinib—pancreatic cancer	0.000383	0.00245	CcSEcCtD
Dapagliflozin—Back pain—Irinotecan—pancreatic cancer	0.000378	0.00242	CcSEcCtD
Dapagliflozin—Angina pectoris—Docetaxel—pancreatic cancer	0.000378	0.00242	CcSEcCtD
Dapagliflozin—Neoplasm—Epirubicin—pancreatic cancer	0.000377	0.00241	CcSEcCtD
Dapagliflozin—Skin disorder—Sunitinib—pancreatic cancer	0.000376	0.00241	CcSEcCtD
Dapagliflozin—Back pain—Gemcitabine—pancreatic cancer	0.000368	0.00236	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—pancreatic cancer	0.000364	0.00233	CcSEcCtD
Dapagliflozin—Blood urea increased—Doxorubicin—pancreatic cancer	0.000364	0.00233	CcSEcCtD
Dapagliflozin—Urticaria—Tamoxifen—pancreatic cancer	0.000359	0.0023	CcSEcCtD
Dapagliflozin—Body temperature increased—Erlotinib—pancreatic cancer	0.000354	0.00226	CcSEcCtD
Dapagliflozin—Phlebitis—Epirubicin—pancreatic cancer	0.000351	0.00225	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—pancreatic cancer	0.000349	0.00223	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Epirubicin—pancreatic cancer	0.000348	0.00223	CcSEcCtD
Dapagliflozin—Infestation NOS—Docetaxel—pancreatic cancer	0.000346	0.00221	CcSEcCtD
Dapagliflozin—Infestation—Docetaxel—pancreatic cancer	0.000346	0.00221	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Docetaxel—pancreatic cancer	0.000341	0.00218	CcSEcCtD
Dapagliflozin—Renal failure—Docetaxel—pancreatic cancer	0.00034	0.00218	CcSEcCtD
Dapagliflozin—Myocardial infarction—Docetaxel—pancreatic cancer	0.000339	0.00217	CcSEcCtD
Dapagliflozin—Hypertension—Irinotecan—pancreatic cancer	0.000338	0.00216	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000335	0.00214	CcSEcCtD
Dapagliflozin—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000333	0.00213	CcSEcCtD
Dapagliflozin—Constipation—Sunitinib—pancreatic cancer	0.000331	0.00212	CcSEcCtD
Dapagliflozin—Discomfort—Irinotecan—pancreatic cancer	0.000329	0.00211	CcSEcCtD
Dapagliflozin—Hypertension—Gemcitabine—pancreatic cancer	0.000329	0.0021	CcSEcCtD
Dapagliflozin—Phlebitis—Doxorubicin—pancreatic cancer	0.000325	0.00208	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Doxorubicin—pancreatic cancer	0.000322	0.00206	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000322	0.00206	CcSEcCtD
Dapagliflozin—Discomfort—Gemcitabine—pancreatic cancer	0.00032	0.00205	CcSEcCtD
Dapagliflozin—Oedema—Irinotecan—pancreatic cancer	0.000319	0.00204	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Irinotecan—pancreatic cancer	0.000319	0.00204	CcSEcCtD
Dapagliflozin—Infection—Irinotecan—pancreatic cancer	0.000317	0.00203	CcSEcCtD
Dapagliflozin—Discomfort—Fluorouracil—pancreatic cancer	0.000315	0.00202	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000311	0.00199	CcSEcCtD
Dapagliflozin—Oedema—Gemcitabine—pancreatic cancer	0.000311	0.00199	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Epirubicin—pancreatic cancer	0.00031	0.00199	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Epirubicin—pancreatic cancer	0.000309	0.00198	CcSEcCtD
Dapagliflozin—Infection—Gemcitabine—pancreatic cancer	0.000309	0.00198	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Irinotecan—pancreatic cancer	0.000309	0.00197	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Docetaxel—pancreatic cancer	0.000307	0.00196	CcSEcCtD
Dapagliflozin—Body temperature increased—Sunitinib—pancreatic cancer	0.000306	0.00196	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000306	0.00196	CcSEcCtD
Dapagliflozin—Oedema—Fluorouracil—pancreatic cancer	0.000306	0.00196	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000305	0.00195	CcSEcCtD
Dapagliflozin—Urethral disorder—Docetaxel—pancreatic cancer	0.000304	0.00195	CcSEcCtD
Dapagliflozin—Hyponatraemia—Epirubicin—pancreatic cancer	0.000304	0.00195	CcSEcCtD
Dapagliflozin—Infection—Fluorouracil—pancreatic cancer	0.000304	0.00194	CcSEcCtD
Dapagliflozin—Pain in extremity—Epirubicin—pancreatic cancer	0.000303	0.00194	CcSEcCtD
Dapagliflozin—Skin disorder—Gemcitabine—pancreatic cancer	0.000302	0.00193	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.000301	0.00192	CcSEcCtD
Dapagliflozin—Dizziness—Tamoxifen—pancreatic cancer	0.000299	0.00191	CcSEcCtD
Dapagliflozin—Hypotension—Irinotecan—pancreatic cancer	0.000298	0.00191	CcSEcCtD
Dapagliflozin—Dizziness—Erlotinib—pancreatic cancer	0.000296	0.00189	CcSEcCtD
Dapagliflozin—Hypotension—Gemcitabine—pancreatic cancer	0.000291	0.00186	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—pancreatic cancer	0.000287	0.00184	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—pancreatic cancer	0.000286	0.00183	CcSEcCtD
Dapagliflozin—Hypotension—Fluorouracil—pancreatic cancer	0.000286	0.00183	CcSEcCtD
Dapagliflozin—Hypersensitivity—Sunitinib—pancreatic cancer	0.000285	0.00183	CcSEcCtD
Dapagliflozin—Rash—Tamoxifen—pancreatic cancer	0.000285	0.00183	CcSEcCtD
Dapagliflozin—Dermatitis—Tamoxifen—pancreatic cancer	0.000285	0.00182	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Epirubicin—pancreatic cancer	0.000284	0.00182	CcSEcCtD
Dapagliflozin—Headache—Tamoxifen—pancreatic cancer	0.000283	0.00181	CcSEcCtD
Dapagliflozin—Rash—Erlotinib—pancreatic cancer	0.000282	0.00181	CcSEcCtD
Dapagliflozin—Dermatitis—Erlotinib—pancreatic cancer	0.000282	0.0018	CcSEcCtD
Dapagliflozin—Dehydration—Epirubicin—pancreatic cancer	0.000282	0.0018	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—pancreatic cancer	0.000281	0.0018	CcSEcCtD
Dapagliflozin—Headache—Erlotinib—pancreatic cancer	0.00028	0.00179	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—pancreatic cancer	0.00028	0.00179	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000277	0.00177	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000276	0.00176	CcSEcCtD
Dapagliflozin—Constipation—Irinotecan—pancreatic cancer	0.000273	0.00175	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000271	0.00173	CcSEcCtD
Dapagliflozin—Malnutrition—Docetaxel—pancreatic cancer	0.00027	0.00173	CcSEcCtD
Dapagliflozin—Nausea—Tamoxifen—pancreatic cancer	0.000269	0.00172	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000268	0.00172	CcSEcCtD
Dapagliflozin—Constipation—Gemcitabine—pancreatic cancer	0.000266	0.0017	CcSEcCtD
Dapagliflozin—Nausea—Erlotinib—pancreatic cancer	0.000266	0.0017	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000264	0.00169	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000262	0.00168	CcSEcCtD
Dapagliflozin—Influenza—Epirubicin—pancreatic cancer	0.000262	0.00167	CcSEcCtD
Dapagliflozin—Back pain—Docetaxel—pancreatic cancer	0.000261	0.00167	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—pancreatic cancer	0.000261	0.00167	CcSEcCtD
Dapagliflozin—Dizziness—Sunitinib—pancreatic cancer	0.000256	0.00164	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000256	0.00164	CcSEcCtD
Dapagliflozin—Angina pectoris—Epirubicin—pancreatic cancer	0.000255	0.00163	CcSEcCtD
Dapagliflozin—Body temperature increased—Irinotecan—pancreatic cancer	0.000252	0.00161	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000251	0.0016	CcSEcCtD
Dapagliflozin—Body temperature increased—Gemcitabine—pancreatic cancer	0.000246	0.00157	CcSEcCtD
Dapagliflozin—Dysuria—Epirubicin—pancreatic cancer	0.000245	0.00157	CcSEcCtD
Dapagliflozin—Rash—Sunitinib—pancreatic cancer	0.000244	0.00156	CcSEcCtD
Dapagliflozin—Dermatitis—Sunitinib—pancreatic cancer	0.000244	0.00156	CcSEcCtD
Dapagliflozin—Urticaria—Fluorouracil—pancreatic cancer	0.000243	0.00155	CcSEcCtD
Dapagliflozin—Headache—Sunitinib—pancreatic cancer	0.000243	0.00155	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—pancreatic cancer	0.000242	0.00155	CcSEcCtD
Dapagliflozin—Pollakiuria—Epirubicin—pancreatic cancer	0.000242	0.00155	CcSEcCtD
Dapagliflozin—Body temperature increased—Fluorouracil—pancreatic cancer	0.000242	0.00155	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—pancreatic cancer	0.000236	0.00151	CcSEcCtD
Dapagliflozin—Hypersensitivity—Irinotecan—pancreatic cancer	0.000235	0.0015	CcSEcCtD
Dapagliflozin—Hypertension—Docetaxel—pancreatic cancer	0.000233	0.00149	CcSEcCtD
Dapagliflozin—Infestation NOS—Epirubicin—pancreatic cancer	0.000233	0.00149	CcSEcCtD
Dapagliflozin—Infestation—Epirubicin—pancreatic cancer	0.000233	0.00149	CcSEcCtD
Dapagliflozin—Nausea—Sunitinib—pancreatic cancer	0.00023	0.00147	CcSEcCtD
Dapagliflozin—Renal failure—Epirubicin—pancreatic cancer	0.000229	0.00147	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000229	0.00146	CcSEcCtD
Dapagliflozin—Urinary tract infection—Epirubicin—pancreatic cancer	0.000227	0.00145	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—pancreatic cancer	0.000226	0.00145	CcSEcCtD
Dapagliflozin—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000225	0.00144	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—pancreatic cancer	0.000224	0.00143	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000221	0.00141	CcSEcCtD
Dapagliflozin—Oedema—Docetaxel—pancreatic cancer	0.000221	0.00141	CcSEcCtD
Dapagliflozin—Infection—Docetaxel—pancreatic cancer	0.000219	0.0014	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—pancreatic cancer	0.000216	0.00138	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—pancreatic cancer	0.000216	0.00138	CcSEcCtD
Dapagliflozin—Skin disorder—Docetaxel—pancreatic cancer	0.000214	0.00137	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—pancreatic cancer	0.000212	0.00136	CcSEcCtD
Dapagliflozin—Dizziness—Irinotecan—pancreatic cancer	0.000211	0.00135	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—pancreatic cancer	0.00021	0.00134	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000207	0.00132	CcSEcCtD
Dapagliflozin—Hypotension—Docetaxel—pancreatic cancer	0.000206	0.00132	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000206	0.00132	CcSEcCtD
Dapagliflozin—Urethral disorder—Epirubicin—pancreatic cancer	0.000205	0.00131	CcSEcCtD
Dapagliflozin—Dizziness—Fluorouracil—pancreatic cancer	0.000202	0.00129	CcSEcCtD
Dapagliflozin—Rash—Irinotecan—pancreatic cancer	0.000201	0.00129	CcSEcCtD
Dapagliflozin—Dermatitis—Irinotecan—pancreatic cancer	0.000201	0.00129	CcSEcCtD
Dapagliflozin—Headache—Irinotecan—pancreatic cancer	0.0002	0.00128	CcSEcCtD
Dapagliflozin—Rash—Gemcitabine—pancreatic cancer	0.000196	0.00125	CcSEcCtD
Dapagliflozin—Dermatitis—Gemcitabine—pancreatic cancer	0.000196	0.00125	CcSEcCtD
Dapagliflozin—Headache—Gemcitabine—pancreatic cancer	0.000195	0.00125	CcSEcCtD
Dapagliflozin—Rash—Fluorouracil—pancreatic cancer	0.000193	0.00123	CcSEcCtD
Dapagliflozin—Dermatitis—Fluorouracil—pancreatic cancer	0.000193	0.00123	CcSEcCtD
Dapagliflozin—Headache—Fluorouracil—pancreatic cancer	0.000191	0.00123	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000191	0.00122	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00019	0.00122	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.00019	0.00122	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—pancreatic cancer	0.00019	0.00122	CcSEcCtD
Dapagliflozin—Nausea—Irinotecan—pancreatic cancer	0.00019	0.00121	CcSEcCtD
Dapagliflozin—Constipation—Docetaxel—pancreatic cancer	0.000189	0.00121	CcSEcCtD
Dapagliflozin—Nausea—Gemcitabine—pancreatic cancer	0.000185	0.00118	CcSEcCtD
Dapagliflozin—Malnutrition—Epirubicin—pancreatic cancer	0.000182	0.00117	CcSEcCtD
Dapagliflozin—Nausea—Fluorouracil—pancreatic cancer	0.000182	0.00116	CcSEcCtD
Dapagliflozin—Back pain—Epirubicin—pancreatic cancer	0.000176	0.00113	CcSEcCtD
Dapagliflozin—Body temperature increased—Docetaxel—pancreatic cancer	0.000174	0.00112	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—pancreatic cancer	0.000169	0.00108	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—pancreatic cancer	0.000163	0.00104	CcSEcCtD
Dapagliflozin—Hypersensitivity—Docetaxel—pancreatic cancer	0.000163	0.00104	CcSEcCtD
Dapagliflozin—Hypertension—Epirubicin—pancreatic cancer	0.000157	0.00101	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000154	0.000987	CcSEcCtD
Dapagliflozin—Discomfort—Epirubicin—pancreatic cancer	0.000153	0.000982	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000149	0.000952	CcSEcCtD
Dapagliflozin—Oedema—Epirubicin—pancreatic cancer	0.000149	0.000952	CcSEcCtD
Dapagliflozin—Infection—Epirubicin—pancreatic cancer	0.000148	0.000946	CcSEcCtD
Dapagliflozin—Dizziness—Docetaxel—pancreatic cancer	0.000146	0.000934	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—pancreatic cancer	0.000146	0.000932	CcSEcCtD
Dapagliflozin—Skin disorder—Epirubicin—pancreatic cancer	0.000145	0.000925	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000144	0.000921	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000143	0.000913	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—pancreatic cancer	0.000142	0.000908	CcSEcCtD
Dapagliflozin—Rash—Docetaxel—pancreatic cancer	0.000139	0.00089	CcSEcCtD
Dapagliflozin—Hypotension—Epirubicin—pancreatic cancer	0.000139	0.00089	CcSEcCtD
Dapagliflozin—Dermatitis—Docetaxel—pancreatic cancer	0.000139	0.000889	CcSEcCtD
Dapagliflozin—Headache—Docetaxel—pancreatic cancer	0.000138	0.000885	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000138	0.000881	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—pancreatic cancer	0.000138	0.000881	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—pancreatic cancer	0.000137	0.000875	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—pancreatic cancer	0.000134	0.000856	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000133	0.000852	CcSEcCtD
Dapagliflozin—Nausea—Docetaxel—pancreatic cancer	0.000131	0.000839	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—pancreatic cancer	0.000129	0.000823	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000128	0.000822	CcSEcCtD
Dapagliflozin—Constipation—Epirubicin—pancreatic cancer	0.000127	0.000814	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000119	0.000761	CcSEcCtD
Dapagliflozin—Urticaria—Epirubicin—pancreatic cancer	0.000118	0.000757	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—pancreatic cancer	0.000118	0.000754	CcSEcCtD
Dapagliflozin—Body temperature increased—Epirubicin—pancreatic cancer	0.000118	0.000753	CcSEcCtD
Dapagliflozin—Hypersensitivity—Epirubicin—pancreatic cancer	0.00011	0.000702	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—pancreatic cancer	0.000109	0.0007	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—pancreatic cancer	0.000109	0.000697	CcSEcCtD
Dapagliflozin—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000101	0.000649	CcSEcCtD
Dapagliflozin—Dizziness—Epirubicin—pancreatic cancer	9.84e-05	0.00063	CcSEcCtD
Dapagliflozin—Rash—Epirubicin—pancreatic cancer	9.38e-05	0.0006	CcSEcCtD
Dapagliflozin—Dermatitis—Epirubicin—pancreatic cancer	9.37e-05	0.0006	CcSEcCtD
Dapagliflozin—Headache—Epirubicin—pancreatic cancer	9.32e-05	0.000597	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—pancreatic cancer	9.11e-05	0.000583	CcSEcCtD
Dapagliflozin—Nausea—Epirubicin—pancreatic cancer	8.84e-05	0.000566	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—pancreatic cancer	8.68e-05	0.000556	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—pancreatic cancer	8.67e-05	0.000555	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—pancreatic cancer	8.63e-05	0.000552	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—pancreatic cancer	8.18e-05	0.000523	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—PPARG—pancreatic cancer	3.55e-05	0.000349	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—PIK3CA—pancreatic cancer	3.51e-05	0.000345	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—SRC—pancreatic cancer	3.5e-05	0.000344	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—SRC—pancreatic cancer	3.5e-05	0.000344	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—TNF—pancreatic cancer	3.49e-05	0.000343	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	3.47e-05	0.000341	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	3.39e-05	0.000333	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—STAT3—pancreatic cancer	3.37e-05	0.000331	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—STAT3—pancreatic cancer	3.37e-05	0.000331	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—NRAS—pancreatic cancer	3.36e-05	0.000331	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—NRAS—pancreatic cancer	3.36e-05	0.000331	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	3.32e-05	0.000327	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GLP1R—pancreatic cancer	3.31e-05	0.000326	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—DPYD—pancreatic cancer	3.26e-05	0.00032	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HRAS—pancreatic cancer	3.25e-05	0.000319	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PIK3CD—pancreatic cancer	3.24e-05	0.000318	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—TYMP—pancreatic cancer	3.17e-05	0.000311	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PTEN—pancreatic cancer	3.16e-05	0.00031	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PTEN—pancreatic cancer	3.16e-05	0.00031	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—MYC—pancreatic cancer	3.13e-05	0.000308	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—MYC—pancreatic cancer	3.13e-05	0.000308	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—TGFB1—pancreatic cancer	3.12e-05	0.000307	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—TGFB1—pancreatic cancer	3.12e-05	0.000307	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PRSS1—pancreatic cancer	3.11e-05	0.000306	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—SLC2A2—pancreatic cancer	3.09e-05	0.000304	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—EGFR—pancreatic cancer	3.06e-05	0.000301	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—EGFR—pancreatic cancer	3.06e-05	0.000301	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.06e-05	0.000301	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	3.03e-05	0.000298	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	3e-05	0.000295	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.95e-05	0.00029	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CD44—pancreatic cancer	2.95e-05	0.00029	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PIK3CA—pancreatic cancer	2.94e-05	0.000289	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—KRAS—pancreatic cancer	2.89e-05	0.000285	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—KRAS—pancreatic cancer	2.89e-05	0.000285	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—AKT1—pancreatic cancer	2.87e-05	0.000282	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GCG—pancreatic cancer	2.82e-05	0.000278	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PIK3CB—pancreatic cancer	2.82e-05	0.000277	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PTGS2—pancreatic cancer	2.79e-05	0.000275	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ARG2—pancreatic cancer	2.7e-05	0.000265	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.69e-05	0.000264	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PIK3CA—pancreatic cancer	2.66e-05	0.000261	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—PIK3CA—pancreatic cancer	2.66e-05	0.000261	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—STK11—pancreatic cancer	2.66e-05	0.000261	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GLP1R—pancreatic cancer	2.55e-05	0.000251	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	2.55e-05	0.000251	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—DPYD—pancreatic cancer	2.51e-05	0.000247	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PRSS1—pancreatic cancer	2.49e-05	0.000244	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HRAS—pancreatic cancer	2.46e-05	0.000242	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HRAS—pancreatic cancer	2.46e-05	0.000242	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PTEN—pancreatic cancer	2.44e-05	0.00024	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—AKT1—pancreatic cancer	2.4e-05	0.000236	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CD44—pancreatic cancer	2.39e-05	0.000235	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—SLC2A2—pancreatic cancer	2.38e-05	0.000234	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	2.37e-05	0.000233	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TYMP—pancreatic cancer	2.36e-05	0.000232	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.34e-05	0.00023	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PRSS1—pancreatic cancer	2.34e-05	0.00023	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PRSS1—pancreatic cancer	2.32e-05	0.000228	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.32e-05	0.000228	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	2.31e-05	0.000227	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GCG—pancreatic cancer	2.29e-05	0.000226	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—TYMS—pancreatic cancer	2.28e-05	0.000225	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	2.28e-05	0.000224	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PIK3CA—pancreatic cancer	2.23e-05	0.000219	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PIK3CA—pancreatic cancer	2.23e-05	0.000219	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	2.22e-05	0.000219	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—AKT1—pancreatic cancer	2.17e-05	0.000214	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—AKT1—pancreatic cancer	2.17e-05	0.000214	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—STK11—pancreatic cancer	2.16e-05	0.000212	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ARG2—pancreatic cancer	2.16e-05	0.000212	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	2.06e-05	0.000203	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ARG2—pancreatic cancer	2.03e-05	0.0002	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.03e-05	0.000199	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ARG2—pancreatic cancer	2.01e-05	0.000198	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	2.01e-05	0.000198	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PRSS1—pancreatic cancer	1.98e-05	0.000195	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.95e-05	0.000191	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GLP1R—pancreatic cancer	1.9e-05	0.000187	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TYMP—pancreatic cancer	1.88e-05	0.000185	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—DPYD—pancreatic cancer	1.87e-05	0.000184	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—APOE—pancreatic cancer	1.86e-05	0.000183	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—TYMS—pancreatic cancer	1.86e-05	0.000183	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	1.85e-05	0.000182	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CD44—pancreatic cancer	1.85e-05	0.000181	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	1.84e-05	0.000181	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—AKT1—pancreatic cancer	1.82e-05	0.000179	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—AKT1—pancreatic cancer	1.82e-05	0.000179	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	1.81e-05	0.000178	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TYMP—pancreatic cancer	1.78e-05	0.000175	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SLC2A2—pancreatic cancer	1.78e-05	0.000175	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GCG—pancreatic cancer	1.77e-05	0.000174	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TYMP—pancreatic cancer	1.76e-05	0.000173	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.76e-05	0.000173	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	1.72e-05	0.000169	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ARG2—pancreatic cancer	1.72e-05	0.000169	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PIK3CA—pancreatic cancer	1.72e-05	0.000169	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	1.71e-05	0.000168	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.7e-05	0.000167	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CG—pancreatic cancer	1.68e-05	0.000165	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—STK11—pancreatic cancer	1.66e-05	0.000164	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PPARG—pancreatic cancer	1.62e-05	0.000159	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	1.57e-05	0.000154	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.54e-05	0.000152	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PRSS1—pancreatic cancer	1.53e-05	0.000151	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GLP1R—pancreatic cancer	1.52e-05	0.000149	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	1.52e-05	0.000149	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—APOE—pancreatic cancer	1.51e-05	0.000148	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TYMP—pancreatic cancer	1.5e-05	0.000148	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—DPYD—pancreatic cancer	1.49e-05	0.000147	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CD—pancreatic cancer	1.47e-05	0.000145	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.45e-05	0.000143	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GLP1R—pancreatic cancer	1.43e-05	0.000141	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—TYMS—pancreatic cancer	1.43e-05	0.000141	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.43e-05	0.000141	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GLP1R—pancreatic cancer	1.42e-05	0.00014	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SLC2A2—pancreatic cancer	1.42e-05	0.000139	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—DPYD—pancreatic cancer	1.41e-05	0.000138	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—AKT1—pancreatic cancer	1.4e-05	0.000138	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—DPYD—pancreatic cancer	1.4e-05	0.000137	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CD44—pancreatic cancer	1.37e-05	0.000135	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CG—pancreatic cancer	1.36e-05	0.000134	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.35e-05	0.000132	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	1.34e-05	0.000131	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.33e-05	0.000131	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ARG2—pancreatic cancer	1.33e-05	0.000131	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	1.32e-05	0.00013	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GCG—pancreatic cancer	1.32e-05	0.00013	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PPARG—pancreatic cancer	1.31e-05	0.000129	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.31e-05	0.000129	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CB—pancreatic cancer	1.28e-05	0.000126	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	1.28e-05	0.000126	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTGS2—pancreatic cancer	1.27e-05	0.000125	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.27e-05	0.000124	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.24e-05	0.000122	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—STK11—pancreatic cancer	1.24e-05	0.000122	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GLP1R—pancreatic cancer	1.21e-05	0.000119	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CD—pancreatic cancer	1.2e-05	0.000118	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—DPYD—pancreatic cancer	1.19e-05	0.000117	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—APOE—pancreatic cancer	1.16e-05	0.000114	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.16e-05	0.000114	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TYMP—pancreatic cancer	1.16e-05	0.000114	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.15e-05	0.000113	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	1.13e-05	0.000111	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.12e-05	0.00011	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTEN—pancreatic cancer	1.11e-05	0.000109	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CD44—pancreatic cancer	1.1e-05	0.000108	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.08e-05	0.000106	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TYMS—pancreatic cancer	1.07e-05	0.000105	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GCG—pancreatic cancer	1.05e-05	0.000104	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CG—pancreatic cancer	1.05e-05	0.000103	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CB—pancreatic cancer	1.04e-05	0.000103	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CD44—pancreatic cancer	1.03e-05	0.000102	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTGS2—pancreatic cancer	1.03e-05	0.000102	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CD44—pancreatic cancer	1.03e-05	0.000101	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PPARG—pancreatic cancer	1.01e-05	9.97e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1e-05	9.88e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	9.95e-06	9.79e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GCG—pancreatic cancer	9.92e-06	9.76e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—STK11—pancreatic cancer	9.9e-06	9.73e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	9.85e-06	9.68e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GCG—pancreatic cancer	9.83e-06	9.67e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GLP1R—pancreatic cancer	9.36e-06	9.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—STK11—pancreatic cancer	9.33e-06	9.17e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—STK11—pancreatic cancer	9.25e-06	9.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CD—pancreatic cancer	9.23e-06	9.08e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—DPYD—pancreatic cancer	9.21e-06	9.05e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTEN—pancreatic cancer	9.02e-06	8.87e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CD44—pancreatic cancer	8.77e-06	8.62e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	8.74e-06	8.59e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	8.68e-06	8.54e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—APOE—pancreatic cancer	8.67e-06	8.53e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	8.58e-06	8.44e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TYMS—pancreatic cancer	8.51e-06	8.37e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	8.5e-06	8.36e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GCG—pancreatic cancer	8.4e-06	8.26e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	8.21e-06	8.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CB—pancreatic cancer	8.05e-06	7.91e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TYMS—pancreatic cancer	8.02e-06	7.89e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS2—pancreatic cancer	7.97e-06	7.84e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TYMS—pancreatic cancer	7.95e-06	7.82e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—STK11—pancreatic cancer	7.9e-06	7.77e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CA—pancreatic cancer	7.83e-06	7.7e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	7.82e-06	7.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARG—pancreatic cancer	7.55e-06	7.43e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	7.42e-06	7.29e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTEN—pancreatic cancer	6.95e-06	6.84e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APOE—pancreatic cancer	6.92e-06	6.81e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	6.88e-06	6.76e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TYMS—pancreatic cancer	6.8e-06	6.68e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CD44—pancreatic cancer	6.76e-06	6.65e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APOE—pancreatic cancer	6.52e-06	6.42e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GCG—pancreatic cancer	6.49e-06	6.38e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOE—pancreatic cancer	6.47e-06	6.36e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—pancreatic cancer	6.4e-06	6.29e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CA—pancreatic cancer	6.36e-06	6.26e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CG—pancreatic cancer	6.25e-06	6.15e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.12e-06	6.02e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—STK11—pancreatic cancer	6.1e-06	6e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARG—pancreatic cancer	6.03e-06	5.93e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	5.99e-06	5.9e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS2—pancreatic cancer	5.94e-06	5.84e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	5.89e-06	5.79e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	5.84e-06	5.74e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARG—pancreatic cancer	5.68e-06	5.59e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARG—pancreatic cancer	5.63e-06	5.54e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOE—pancreatic cancer	5.53e-06	5.44e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CD—pancreatic cancer	5.49e-06	5.4e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TYMS—pancreatic cancer	5.25e-06	5.16e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.23e-06	5.15e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—pancreatic cancer	5.2e-06	5.11e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTEN—pancreatic cancer	5.18e-06	5.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	5.18e-06	5.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	5.13e-06	5.05e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	4.99e-06	4.91e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CA—pancreatic cancer	4.91e-06	4.82e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARG—pancreatic cancer	4.81e-06	4.73e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CB—pancreatic cancer	4.79e-06	4.71e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS2—pancreatic cancer	4.74e-06	4.67e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	4.51e-06	4.44e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	4.47e-06	4.4e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS2—pancreatic cancer	4.47e-06	4.4e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS2—pancreatic cancer	4.43e-06	4.36e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	4.39e-06	4.31e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOE—pancreatic cancer	4.27e-06	4.2e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTEN—pancreatic cancer	4.14e-06	4.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—pancreatic cancer	4.01e-06	3.94e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTEN—pancreatic cancer	3.9e-06	3.83e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTEN—pancreatic cancer	3.87e-06	3.8e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.85e-06	3.79e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	3.82e-06	3.76e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS2—pancreatic cancer	3.79e-06	3.72e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARG—pancreatic cancer	3.72e-06	3.65e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	3.65e-06	3.59e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	3.38e-06	3.33e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTEN—pancreatic cancer	3.3e-06	3.25e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—pancreatic cancer	2.99e-06	2.94e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.95e-06	2.9e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.92e-06	2.87e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.92e-06	2.87e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.75e-06	2.7e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	2.73e-06	2.68e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.55e-06	2.51e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—pancreatic cancer	2.38e-06	2.34e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	2.33e-06	2.29e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.25e-06	2.21e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—pancreatic cancer	2.23e-06	2.19e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.9e-06	1.87e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.8e-06	1.77e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.47e-06	1.44e-05	CbGpPWpGaD
